On November 20, 2012, the Journal of Psychopharmacology published online the outstanding results of our long-term follow-up of subjects who participated in our initial proof of principle study of MDMA-assisted …
On June 20, 2012, the results of our long-term follow-up of subjects who participated in the initial proof of principle study of MDMA-assisted psychotherapy for PTSD were accepted for publication by the …
On April 16, 2012, Dr. Michael Mithoefer, the lead investigator for our recently completed long-term follow-up of subjects who participated in the initial U.S. proof of principle study, submitted a revised …
On March 27, 2012, reviewers for a scientific journal responded with their comments on the paper describing the results of our long-term follow-up of subjects who participated in our initial U.S. proof …
On February 5, 2012, after extensive work, the lead investigator of our first U.S. study of MDMA-assisted psychotherapy for PTSD and co-authors submitted a paper describing the results of our long-term …
On June 9, 2011, our Institutional Review Board (IRB) approved the protocol for our new “relapse study” of MDMA-assisted psychotherapy for PTSD. The Food and Drug Administration approved the …
On May 24, 2011, the FDA approved our study of MDMA-assisted psychotherapy for up to three subjects whose PTSD symptoms returned after participating in our flagship Phase 2 clinical trial of MDMA-assisted …
On Dec. 9, 2010, MAPS’ clinical research team submitted our annual report about MAPS’ MDMA/PTSD research to the FDA. Annual reports are designed to give the FDA an overview of completed, ongoing, …
On Nov. 5, 2010, at the International Society for Traumatic Stress Studies annual conference in Montreal, Michael Mithoefer, M.D., presented findings, in poster form, from the long-term follow portion …
MAPS’ clinical research team completed their review of the data from our flagship MDMA/PTSD study. On Nov. 10, the team closed and locked the database, officially bringing the data collection phase …
From Sept. 27 to Oct. 1, Clinical Research Associate Berra Yazar-Klosinski, Ph.D. and Clinical Program Manager Amy Emerson were in Charleston, SC, where they archived the research data from our first U.S. …
On Sept. 27, we completed the long-term follow-up study to our initial US MDMA/PTSD pilot study. Our team is now diligently working on preparing a scientific paper about the results. This study demonstrated …
